Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 3/20 | 0.50 |
| ▸ | PPARG | P37231 | 1/20 | 0.48 |
| ▸ | PPARA | Q07869 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.44 |
| ▸ | MEN1 | O00255 | 2/20 | 0.44 |
| ▸ | PTGER1 | P34995 | 1/20 | 0.43 |
| ▸ | PTGFR | P43088 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12930788 | 0.85 | TAAR1 (0.50) | TAAR1ALDH1A1KMT2AMEN1GAA | |
| SCHEMBL27728237 | 0.84 | TSHR (0.46) | TAAR1PPARGPPARAALDH1A1KMT2A | |
| SCHEMBL22444963 | 0.84 | SLC1A5 (0.53) | TAAR1PPARGPPARA | |
| SCHEMBL16148359 | 0.84 | SLC1A5 (0.53) | TAAR1PPARGPPARA | |
| SCHEMBL16148360 | 0.84 | SLC1A5 (0.53) | TAAR1PPARGPPARA | |
| SCHEMBL31691522 | 0.84 | SLC1A5 (0.53) | TAAR1PPARGPPARA | |
| SCHEMBL3589962 | 0.81 | GAA (0.52) | TAAR1ALDH1A1KMT2AMEN1GAA | |
| SCHEMBL7565996 | 0.80 | TDP1 (0.50) | TAAR1ALDH1A1KMT2AMEN1GAA | |
| SCHEMBL31369510 | 0.80 | TAAR1 (0.49) | TAAR1PPARGPPARAALDH1A1KMT2A | |
| SCHEMBL27486945 | 0.80 | MEN1 (0.43) | TAAR1PPARGPPARAALDH1A1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8877779-B2 | Benzimidazole compound and pharmaceutical use thereof | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2014-11-04 | — | — | US | disclosed |
| US-20100120841-A1 | BENZIMIDAZOLE COMPOUND AND PHARMACEUTICAL USE THEREOF | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2010-05-13 | — | — | US | disclosed |
| EP-2128154-A1 | BENZIMIDAZOLE COMPOUND AND PHARMACEUTICAL USE THEREOF | Mitsubishi Tanabe Pharma Corporation (JP) | 2009-12-02 | — | — | EP | disclosed |
| EP-0987248-B1 | Amide derivatives and their therapeutic use | WELLCOME FOUND (GB) | 2002-09-04 | — | — | EP | disclosed |
| US-6124284-A | REDUCED SIDE EFFECTS | GLAXO WELLCOME INC. (US) | 2000-09-26 | — | — | US | disclosed |
| EP-0987248-A1 | Amide derivatives and their therapeutic use | THE WELLCOME FOUNDATION LIMITED (GB) | 2000-03-22 | — | — | EP | disclosed |
| US-5872118-A | RELAXATION OF SKELETAL MUSCLE IN SPASTIC, HYPERTONIC AND HYPERKINETIC CONDITIONS | GLAXO WELLCOME INC. (US) | 1999-02-16 | — | — | US | disclosed |
| CN-1041720-C | Bicyclic amide derivatives, preparation method thereof, pharmaceutical composition and pharmaceutical application thereof | WELLCOME FOUND (GB) | 1999-01-20 | — | — | CN | disclosed |
| CN-1125938-A | Bicyclic amide derivatives and their use as muscle relaxants | WELLCOME FOUND (GB) | 1996-07-03 | — | — | CN | disclosed |
| EP-0699180-A1 | BICYCLIC AMIDE DERIVATIVES AND THEIR USE AS MUSCLE RELAXANTS | THE WELLCOME FOUNDATION LIMITED (GB) | 1996-03-06 | — | — | EP | disclosed |
| WO-1994026693-A1 | BICYCLIC AMIDE DERIVATIVES AND THEIR USE AS MUSCLE RELAXANTS | THE WELLCOME FOUNDATION LIMITED (GB) | 1994-11-24 | — | — | WO | disclosed |
| WO-1994026692-A1 | BICYCLIC AMIDE DERIVATIVES AND THEIR USE AS MUSCLE RELAXANTS | THE WELLCOME FOUNDATION LIMITED (GB) | 1994-11-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100120841-A1 | BENZIMIDAZOLE COMPOUND AND PHARMACEUTICAL USE THEREOF | ORMDL3, OXA1L, OGFRL1 | TAAR1 875/4885PPARG 120/4885PPARA 122/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.